Giredestrant Approval
Up to 40% of people with hormone receptor-positive metastatic breast cancer develop ESR1 mutations, which help tumours escape standard hormone therapy. On November 16, the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults whose advanced breast cancer carries one of these mutations, four weeks ahead of the agency's goal date.

Key Takeaways
- The approval covers ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after prior endocrine therapy.
- In the phase 3 evERA trial, the all-oral combination cut the risk of progression or death by 62% versus standard endocrine therapy plus everolimus in patients with ESR1 mutations.
- A liquid-biopsy test, FoundationOne Liquid CDx, will identify eligible patients.
Who Qualifies
Giredestrant, developed by Roche's Genentech unit, is an oral drug that blocks and degrades the estrogen receptor, a class known as SERDs. Patients take it with everolimus, an mTOR inhibitor that also comes as a tablet.
The label covers adults whose disease came back during or after endocrine-based adjuvant therapy. It also covers those whose cancer progressed on at least one endocrine-based treatment in the metastatic setting.
An FDA-authorized test must confirm the ESR1 mutation. The FDA named FoundationOne Liquid CDx, which analyses circulating tumour DNA from a blood sample, as the companion diagnostic.
What evERA Found
The open-label evERA trial enrolled 373 adults with ER-positive, HER2-negative disease, including 207 with ESR1-mutated tumours. Researchers randomly assigned 183 patients to giredestrant 30 mg daily and 190 to their physician's choice of exemestane, fulvestrant or tamoxifen. Both groups also took everolimus 10 mg daily.
In patients with ESR1 mutations, median progression-free survival reached 10 months on the giredestrant combination, against 5.5 months on the comparator. The hazard ratio was 0.38, a 62% reduction in the risk of progression or death.
Tumours shrank in 27% of those patients on giredestrant, compared with 14% in the control arm. Overall survival data are not yet mature. Across the whole trial population, the combination reduced the risk of progression or death by 44%.
The New England Journal of Medicine published the trial results.
Side Effects and Dosing
The most common side effects, seen in at least 20% of patients, were mouth sores (stomatitis), rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea. The label also warns about a slow heart rate (bradycardia) and harm to a developing fetus.
The recommended dose is 30 mg once daily, with or without food.
The FDA reviewed the drug under Project Orbis together with Health Canada and Israel's Ministry of Health.
What Roche Says
“By pairing potent oestrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen,” said Levi Garraway, Roche's chief medical officer and head of global product development.
Dr Erica L. Mayer of the Dana-Farber Cancer Institute said the regimen “directly targets the primary genomic drivers of resistance”.
A second decision is close. The FDA is reviewing Wilserdly as adjuvant therapy for stage I to III breast cancer at intermediate to high risk of recurrence, with a target date of November 30. Approval there would make it the first SERD cleared for both early and advanced ER-positive disease.
Oral Options Gain Ground
ESR1 mutations usually emerge under pressure from hormone therapy, so doctors increasingly test for them when the disease progresses. The evERA results, discussed in detail by trial investigators, showed consistent benefit across key patient subgroups. That supports pairing a SERD with targeted drugs once CDK4/6 inhibitors stop working. When the FDA accepted the application in February, the combination was on track to become the first oral SERD regimen in that post-CDK4/6 setting.
The decision adds to a busy stretch for the agency. It recently rejected Summit's ivonescimab for lung cancer over survival data and granted tentative approval to a generic lenacapavir shot, while gene-editing firm Beam reported pivotal sickle cell data. For patients with ESR1-mutated disease, the practical gain is a regimen taken at home, without the injections that fulvestrant requires.
Written by Vytautas Valinskas
